

REMARKS**I. Claim Status**

Claims 1-37 remain in the application.

Claims 1, 26-27, 29, 30, 36 and 37 have been amended.

II. Double Patenting

Claims 1-37 stand provisionally rejected based on the judicially created doctrine of obviousness-double patenting over claims 1-32 of co-pending Application No. 09/902,845 (which has subsequently issued as United States Patent No 7,084,152). The co-pending application is not commonly owned with the instant application. The claims of the present application are drawn to the treatment of urinary incontinence which is neither taught nor suggested in the co-pending application 09/902,845. In fact, urinary incontinence is not even mentioned in the 09/902,845 application. Accordingly, Applicants respectfully submit that the claims of the presently pending application are patentable over Application No. 09/902,845 (now United States Patent No 7,084,152).

III. Claim Objections

Claims 26-27, 29 and 30 have been amended to delete the term "OMe" and replaced with "OMe".

IV. Rejection Under 35 U.S.C. § 112

Claims 1-37 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly not providing an enablement for making the compounds recited in the claims. Applicants respectfully draw the Examiner's attention to page 14, lines 17-20 of the specification wherein reference to International Application WO 2002/04455 is made. This International Application teaches how to make the compounds recited in the claims. Accordingly, Applicants respectfully request reconsideration and withdrawal of the rejection under 35 U.S.C. §112.

III. Conclusion


In view of the amendments and remarks made above, Applicants believe that this application is now in condition for allowance. Reconsideration and allowance of claims 1-37 is respectfully requested.

The Commissioner is authorized to charge any fee or credit any over payment in connection with this communication to our Deposit Account No. 23-0455.

Respectfully submitted,

Dated: _____

9/28/06



David R. Kurlandsky
Registration No. 41,505
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, Michigan 48105
Telephone: (734) 622-7304
Facsimile: (734) 622-1553